Publications by authors named "Sarah Elyoussfi"
Psoriasis (Ps) is a debilitating immune-mediated chronic skin condition. It affects about 1-3% of the world population, with an 8-11% prevalence in Northern European populations. Tyrosine kinase 2 (TYK2) is a newly identified target for Ps.
View Article and Find Full Text PDFIntroduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 60 million people worldwide. Genome-wide association studies (GWAS) have allowed identification of novel therapeutic targets in psoriasis including tyrosine kinase 2 (TYK2) where an exonic variant within the gene increases the risk of developing psoriasis.
Areas Covered: This review discusses the role of TYK2 in psoriasis pathogenesis, how that relates to genetic variants and recently published ground-breaking clinical trials of novel TYK2 inhibitors.
Article Synopsis
- Biosimilars can potentially lower costs for treating moderate-to-severe psoriasis, but their effectiveness and safety for this condition remain uncertain since they are often approved based on data from other diseases.
- The objective of the review was to analyze and compare the efficacy and safety of biosimilars versus their originator biologics specifically for psoriasis treatment.
- The review included 14 trials and 3 cohort studies, finding no significant differences in treatment outcomes or adverse events between biosimilars and originators, though some studies indicated a higher risk of adverse events in patients who switched to biosimilars.
Background: IgG4-related disease (IgG4-RD) is a systemic multi-organ inflammatory disorder which affects the kidney 20% of the time. Patients with intrinsic IgG4-related kidney disease (IgG4-RKD) often have tubulointerstitial nephritis (TIN) whereas glomerular lesions like membranous nephropathy (MN) are less common. Antibodies to thrombospondin type-1 domain-containing 7A (THSD7A) have been described in primary MN, but never in association with IgG4-RKD.
View Article and Find Full Text PDFThe diverse clinical picture of PsA suggests the need to identify suitable therapies to address the different combinations of clinical manifestations. This review aimed to classify the available biologic agents and new small molecule inhibitors (licensed and nonlicensed) based on their proven efficacy in treating different clinical manifestations associated with psoriasis and PsA. This review presents the level of evidence of efficacy of different biologic treatments and small molecule inhibitors for certain clinical features of treatment of PsA and psoriasis, which was graded in categories I-IV.
View Article and Find Full Text PDF